factor VIII CRISPR/Cas9-gene therapy (Casebia)

N/A

Report date: 2025/08/13 15:21:04

Base Information

Drug Namefactor VIII CRISPR/Cas9-gene therapy (Casebia)

Drug Alias NameAAV8-FVIII LNP

ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector

Mechanisms of ActionCoagulation factor VIII stimulants

TargetsCoagulation factor VIII

Therapy Area/IndicationsHemophilia A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCasebia Therapeutics Llc

China Registration ClassN/A

Develop Information

Active CompaniesCasebia Therapeutics Llc

Inactive CompaniesN/A

Active IndicationsHemophilia A

Inactive IndicationsN/A

Other Information

ATC CodeN/A